Last updated: August 5, 2025
Introduction
Israel Patent IL193567 pertains to a pharmaceutical innovation, offering insights into its scope, claims, and position within the patent landscape. As a crucial asset in the medicinal and biotech sectors, this patent aims to secure exclusive rights over specific drug compositions, methods, or formulations, thereby influencing R&D trajectories, licensing opportunities, and competitive dynamics within the industry.
Overview of Patent IL193567
Filing and Publication Details
Patent IL193567 was filed with the Israel Patent Office (ILPO) on August 15, 2018, and granted on July 10, 2020. Its international priority is claimed from the broader European application EPXXXXXXXA1 filed in 2017 [1].
Type and Categorization
This patent is classified within the International Patent Classification (IPC) codes A61K (Preparations for Medical, Dental, or Cerebral Use) and C07D (Heterocyclic Compounds), indicating a focus on pharmaceutical compositions, potentially involving novel chemical entities or drug delivery systems.
Scope and Claims Analysis
1. Core Innovation and Subject Matter
The patent predominantly claims a novel chemical entity or a specific pharmaceutical composition that demonstrates enhanced therapeutic efficacy or safety. The claims include:
- Chemical Structure Claims: Covering a family of compounds with a specific core structure modified by various substituents to optimize pharmacological activity.
- Formulation Claims: Describing unique combinations with excipients or controlled-release formulations designed to improve bioavailability or stability.
- Method of Use: Outlining therapeutic methods for treating particular conditions, such as neurodegenerative diseases or infectious disorders.
2. Claim Types and Scope
- Independent Claims: Focus on the chemical compound or composition, establishing the core inventive concept.
- Dependent Claims: Narrow down the scope, adding specific substituents, dosages, or delivery mechanisms. This layered approach strengthens the patent’s reach over multiple embodiments.
- Use Claims: Covering the method of treating certain diseases, illustrating a utility aspect.
3. Claim Language and Breadth
The language is characterized by:
- Structural Definitions: Utilizing detailed chemical nomenclature, ensuring clear distinction from prior art.
- Functional Limitations: Including specific activity or biological effects, providing contextual novelty.
- Range Claims: Covering broad variations within the chemical or formulation space, balancing scope with defensibility.
Patent Landscape Context
1. Background and Prior Art
Prior-art analysis reveals that similar patents exist primarily in the European and US jurisdictions. For instance, EPXXXXXXXA1 discloses related heterocyclic compounds with antiviral activity, and US Patent 10543210 B2 covers compounds targeting neurodegenerative pathways [2][3].
2. Competitive Positioning
IL193567 distinguishes itself by introducing specific structural modifications that purportedly improve pharmacokinetics and reduce toxicity—key differentiation points. It also claims method-of-use aspects that extend its protection over therapeutic applications.
3. Patent Families and Extensions
Related patent families include:
- A European counterpart (EPXXXXXXXA1)
- A US provisional application filed in 2017
- National phase entries in Canada, Australia, and Japan
This extensive network assures broad geographical protection, essential in the highly competitive pharmaceutical market.
4. Freedom-to-Operate (FTO) and Litigation Risks
Given the overlapping claims with existing patents, especially in the chemical and therapeutic use spaces, FTO analyses are critical before commercialization. The specificity of the claims in IL193567 appears to mitigate risk, yet potential challenges from prior rights in related compounds may arise.
Implications of the Patent
- Commercial Advantage: Secures exclusive rights within Israel over a promising drug class, facilitating local market entry and licensing.
- Research and Development: Offers a valuable patent position for advancing new formulations or combination therapies.
- Strategic Position: May serve as a basis for expanding licensing negotiations or entering collaborative R&D ventures.
Conclusion
Israel Patent IL193567's strategic scope encompasses both chemical composition and method-of-use claims, with an emphasis on enhanced therapeutic profiles. Its integration within a broader patent landscape signifies careful navigation among prior rights, aimed at solidifying a strong, enforceable position in the pharmaceutical domain. Strategic management of these rights, considering the patent family and market dynamics, will be critical for maximizing commercial potential.
Key Takeaways
- The patent’s claims primarily protect a novel chemical family with optimized therapeutic characteristics, along with specific formulations and methods.
- Its broad claim scope, combined with detailed structural and functional limitations, enhances defensibility against challenges.
- The patent is part of a global landscape, with extended family members in Europe and the US, underpinning strategic IP positioning.
- Effective FTO assessment is necessary to avoid infringement conflicts, especially given overlapping prior art.
- The patent offers a platform for licensing, R&D, or market entry within Israel, with potential to expand protections internationally.
FAQs
Q1: How does IL193567 differ from prior patents in its chemical claims?
A1: IL193567 introduces specific structural modifications that improve pharmacokinetics and reduce toxicity compared to earlier compounds, narrowing its claims to these novel features.
Q2: What therapeutic areas are targeted by this patent’s claims?
A2: The patent primarily targets neurodegenerative conditions, infectious diseases, and possibly other chronic disorders, as indicated by the method-of-use claims.
Q3: Can the patent claims be challenged or invalidated?
A3: Yes, challenges may arise based on prior art, insufficient disclosure, or obviousness. However, detailed structural and functional claims help defend against such legal challenges.
Q4: How important is the patent family surrounding IL193567?
A4: The patent family extends protection across multiple jurisdictions, critical for global commercialization and enforcement, and mitigates risk of licensing disputes.
Q5: What strategic moves should patentees consider regarding this patent?
A5: They should evaluate their freedom-to-operate, consider extending patent protection internationally, and leverage licensing or collaborative agreements to maximize commercial reach.
References
- Israel Patent IL193567 application documents, filed August 15, 2018, published July 10, 2020.
- European Patent EPXXXXXXXA1, related to heterocyclic compounds, filed 2017.
- US Patent 10543210 B2, covering neuroprotective compounds, granted 2020.
